I’m an obesity expert and can’t wait for the compounding craze to stop
If you can't name the medical reason your patient needs a knockoff GLP-1, you don't have one.
Read Full Article on FortuneAI SUMMARY
# Summary The article critiques compounding pharmacies that are manufacturing cheaper, unregulated alternatives to branded GLP-1 drugs (like Ozempic and Wegovy) without clear medical justification, raising concerns about quality control and patient safety. This trend poses significant downside risk for pharmaceutical companies like Novo Nordisk and Eli Lilly by potentially eroding prescription volumes and pricing power for their proprietary GLP-1 products as demand shifts to lower-cost compounded versions.
MENTIONED STOCKS
More Finance News
‘We need to trust our employees’: This billionaire CEO went from counting cars in the parking lot past 6pm to embracing hybrid work
How to be tough, not a jerk — and why most people get toughness wrong
AI will create more jobs than it kills, McKinsey says. The catch: 11 million Americans may need new careers
Meta is building one of the world’s biggest undersea cable networks—it’s just one piece of a growing seafloor empire spanning 6 continents
Nitin Nohria: Why it’s so hard for CEOs to stay grounded
Content sourced from Fortune. Not financial advice.